MedTrace Logo

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

NCT02514681 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2025-09-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer patients for previously treated with pertuzumab

Conditions

  • HER2-positive Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG

Trastuzumab

DRUG

Pertuzumab

DRUG

Docetaxel

DRUG

Paclitaxel

DRUG

Nab-paclitaxel

DRUG

Vinorelbine

DRUG

Eribulin

DRUG

Capecitabine

DRUG

Gemcitabine

Sponsors & Collaborators

  • Chugai Pharmaceutical

    collaborator INDUSTRY

  • Japan Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Hiroji Iwata, MD, PhD · Aichi Cancer Center Hospital

  • Yutaka Yamamoto, MD, PhD · Kumamoto University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-01
Primary Completion
2018-12-31
Completion
2022-08-10

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02514681 on ClinicalTrials.gov